Search

Your search keyword '"Ederhy, Stephane"' showing total 262 results
Start Over Author "Ederhy, Stephane" Search Limiters Available in Library Collection
262 results on '"Ederhy, Stephane"'

1. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.

Author

Lehmann, Lorenz, Heckmann, Markus, Bailly, Guillaume, Finke, Daniel, Procureur, Adrien, Power, John, Stein, Frederic, Bretagne, Marie, Ederhy, Stephane, Fenioux, Charlotte, Hamwy, Omar, Funck-Brentano, Elisa, Romano, Emanuela, Pieroni, Laurence, Münster, Jan, Allenbach, Yves, Anquetil, Céline, Leonard-Louis, Sarah, Palaskas, Nicolas, Hayek, Salim, Katus, Hugo, Giannitsis, Evangelos, Frey, Norbert, Kaya, Ziya, Moslehi, Javid, Prifti, Edi, and Salem, Joe-Elie

Subjects
biomarkers, drug-related side effects and adverse reactions, immune checkpoint inhibitors, myocarditis, pharmacology, troponins, Humans, Myocarditis, Immune Checkpoint Inhibitors, Biomarkers, Creatine Kinase, Prognosis, Troponin T
Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but can result in ICI-associated myocarditis, an infrequent but life-threatening condition. Elevations in cardiac biomarkers, specifically troponin-I (cTnI), troponin-T (cTnT), and creatine kinase (CK), are used for diagnosis. However, the association between temporal elevations of these biomarkers with disease trajectory and outcomes has not been established. METHODS: We analyzed the diagnostic accuracy and prognostic performances of cTnI, cTnT, and CK in patients with ICI myocarditis (n=60) through 1-year follow-up in 2 cardio-oncology units (APHP Sorbonne, Paris, France and Heidelberg, Germany). A total of 1751 (1 cTnT assay type), 920 (4 cTnI assay types), and 1191 CK sampling time points were available. Major adverse cardiomyotoxic events (MACE) were defined as heart failure, ventricular arrhythmia, atrioventricular or sinus block requiring pacemaker, respiratory muscle failure requiring mechanical ventilation, and sudden cardiac death. Diagnostic performance of cTnI and cTnT was also assessed in an international ICI myocarditis registry. RESULTS: Within 72 hours of admission, cTnT, cTnI, and CK were increased compared with upper reference limits (URLs) in 56 of 57 (98%), 37 of 42 ([88%] P=0.03 versus cTnT), and 43 of 57 ([75%] P

Published
2023

2. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.

Author

Nowatzke, Joseph, Guedeney, Paul, Palaskas, Nicholas, Lehmann, Lorenz, Ederhy, Stephane, Zhu, Han, Cautela, Jennifer, Francis, Sanjeev, Courand, Pierre-Yves, Deswal, Anita, Ewer, Steven, Aras, Mandar, Arangalage, Dimitri, Ghafourian, Kambiz, Fenioux, Charlotte, Finke, Daniel, Peretto, Giovanni, Zaha, Vlad, Itzhaki Ben Zadok, Osnat, Tajiri, Kazuko, Akhter, Nausheen, Levenson, Joshua, Baldassarre, Lauren, Salem, Joe-Elie, Huang, Shi, Collet, Jean-Philippe, Power, John, and Moslehi, Javid

Subjects
Acute coronary syndrome, Coronary revascularization, Immune checkpoint blockers, Immune-related adverse events, Myocarditis, Humans, Coronary Artery Disease, Immune Checkpoint Inhibitors, Retrospective Studies, Myocarditis, Prognosis, Registries, Risk Factors
Abstract

PURPOSE: Immune checkpoint blocker (ICB) associated myocarditis (ICB-myocarditis) may present similarly and/or overlap with other cardiac pathology including acute coronary syndrome presenting a challenge for prompt clinical diagnosis. METHODS: An international registry was used to retrospectively identify cases of ICB-myocarditis. Presence of coronary artery disease (CAD) was defined as coronary artery stenosis >70% in patients undergoing coronary angiogram. RESULTS: Among 261 patients with clinically suspected ICB-myocarditis who underwent a coronary angiography, CAD was present in 59/261 patients (22.6%). Coronary revascularization was performed during the index hospitalisation in 19/59 (32.2%) patients. Patients undergoing coronary revascularization less frequently received steroids administration within 24 h of admission compared to the other groups (p = 0.029). Myocarditis-related 90-day mortality was 9/17 (52.7%) in the revascularised cohort, compared to 5/31 (16.1%) in those not revascularized and 25/156 (16.0%) in those without CAD (p = 0.001). Immune-related adverse event-related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 6/31 (19.4%) in those not revascularized and 31/156 (19.9%) in no CAD groups (p = 0.007). All-cause 90-day mortality was 11/17 (64.7%) in the revascularized cohort, compared to 13/31 (41.9%) in no revascularization and 60/158 (38.0%) in no CAD groups (p = 0.10). After adjustment of age and sex, coronary revascularization remained associated with ICB-myocarditis-related death at 90 days (hazard ratio [HR] = 4.03, 95% confidence interval [CI] 1.84-8.84, p

Published
2022

3. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.

Author

Nguyen, Lee, Bretagne, Marie, Arrondeau, Jennifer, Zahr, Noel, Ederhy, Stephane, Abbar, Baptiste, Pinna, Bruno, Allenbach, Yves, Mira, Jean-Paul, Moslehi, Javid, Rosenzwajg, Michelle, and Salem, Joe-Elie

Subjects
autoimmunity, case reports, immunotherapy, Abatacept, Adult, Humans, Immune Checkpoint Inhibitors, Male, Myocarditis, Nitriles, Pyrazoles, Pyrimidines
Abstract

Immune-checkpoint inhibitors (ICI) have revolutionized cancer therapy but are associated with infrequent but lethal myocarditis, for which management remains uncertain. Abatacept, a CTLA-4 fusion protein targeting CD86 on antigen presenting cells and leading to global T-cell anergy, has been described as a potential treatment in individual reports. Yet, abatacept treatment dosage, schedule and optimal combination with other immunosuppressive therapies are unclear. We describe a 25-year-old man who developed pembrolizumab (anti-PD1)-induced myocarditis 14 days after first injection for thymoma treatment, which deteriorated into cardiogenic shock, with sustained ventricular arrhythmia, requiring urgent extracorporeal life support implantation, despite prompt initiation of corticosteroids and mycophenolate-mofetil. Using a strategy of serial measurement ensuring with a target of >80% CD86 receptor occupancy on circulating monocytes, abatacept dose was adjusted and combined with ruxolitinib and methylprednisolone. This strategy resulted in high-dose of abatacept: 60 mg/kg in three doses (20 mg/kg each) within the first 10 days, followed by two doses. Clinical improvement occurred within 7 days, with resolution of systolic cardiac dysfunction, and ventricular arrhythmias resulting in successful discharge from hospital. We reversed a case of nearly lethal ICI-myocarditis, using specific patient-dose adjusted abatacept, which may serve as basis for personalized treatment of patients with severe ICI-adverse events. Trial registration number: NCT04294771.

Published
2022

4. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database.

Author

Nguyen, Lee, Cooper, Leslie, Kerneis, Mathieu, Funck-Brentano, Christian, Silvain, Johanne, Brechot, Nicolas, Hekimian, Guillaume, Ammirati, Enrico, Ben MBarek, Badr, Redheuil, Alban, Gandjbakhch, Estelle, Bihan, Kevin, Lebrun-Vignes, Bénédicte, Ederhy, Stephane, Dolladille, Charles, Moslehi, Javid, and Salem, Joe-Elie

Subjects
Adverse Drug Reaction Reporting Systems, Antineoplastic Agents, Antipsychotic Agents, Bayes Theorem, Cross-Sectional Studies, Data Management, Databases, Factual, Humans, Immunotherapy, Myocarditis, Pharmaceutical Preparations, Pharmacovigilance, Systems Analysis, World Health Organization
Abstract

While multiple pharmacological drugs have been associated with myocarditis, temporal trends and overall mortality have not been reported. Here we report the spectrum and main features of 5108 reports of drug-induced myocarditis, in a worldwide pharmacovigilance analysis, comprising more than 21 million individual-case-safety reports from 1967 to 2020. Significant association between myocarditis and a suspected drug is assessed using disproportionality analyses, which use Bayesian information component estimates. Overall, we identify 62 drugs associated with myocarditis, 41 of which are categorized into 5 main pharmacological classes: antipsychotics (n = 3108 reports), salicylates (n = 340), antineoplastic-cytotoxics (n = 190), antineoplastic-immunotherapies (n = 538), and vaccines (n = 790). Thirty-eight (61.3%) drugs were not previously reported associated with myocarditis. Antipsychotic was the first (1979) and most reported class (n = 3018). In 2019, the two most reported classes were antipsychotics (54.7%) and immunotherapies (29.5%). Time-to-onset between treatment start and myocarditis is 15 [interquartile range: 10; 23] days. Subsequent mortality is 10.3% and differs between drug classes with immunotherapies the highest, 32.5% and salicylates the lowest, 2.6%. These elements highlight the diversity of presentations of myocarditis depending on drug class, and show the emerging role of antineoplastic drugs in the field of drug-induced myocarditis.

Published
2022

6. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.

Author

Thavendiranathan, Paaladinesh, Zhang, Lili, Zafar, Amna, Drobni, Zsofia D, Mahmood, Syed S, Cabral, Marcella, Awadalla, Magid, Nohria, Anju, Zlotoff, Daniel A, Thuny, Franck, Heinzerling, Lucie M, Barac, Ana, Sullivan, Ryan J, Chen, Carol L, Gupta, Dipti, Kirchberger, Michael C, Hartmann, Sarah E, Weinsaft, Jonathan W, Gilman, Hannah K, Rizvi, Muhammad A, Kovacina, Bojan, Michel, Caroline, Sahni, Gagan, González-Mansilla, Ana, Calles, Antonio, Fernández-Avilés, Francisco, Mahmoudi, Michael, Reynolds, Kerry L, Ganatra, Sarju, Gavira, Juan José, González, Nahikari Salterain, García de Yébenes Castro, Manuel, Kwong, Raymond Y, Jerosch-Herold, Michael, Coelho-Filho, Otavio R, Afilalo, Jonathan, Zataraín-Nicolás, Eduardo, Baksi, A John, Wintersperger, Bernd J, Calvillo-Arguelles, Oscar, Ederhy, Stephane, Yang, Eric H, Lyon, Alexander R, Fradley, Michael G, and Neilan, Tomas G

Abstract

Myocarditis is a potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 mapping in ICI myocarditis are limited.This study sought to assess the value of CMR T1 and T2 mapping in patients with ICI myocarditis.In this retrospective study from an international registry of patients with ICI myocarditis, clinical and CMR findings (including T1 and T2 maps) were collected. Abnormal T1 and T2 were defined as 2 SD above site (vendor/field strength specific) reference values and a z-score was calculated for each patient. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block.Of 136 patients with ICI myocarditis with a CMR, 86 (63%) had T1 maps and 79 (58%) also had T2 maps. Among the 86 patients (66.3 ± 13.1 years of age), 36 (41.9%) had a left ventricular ejection fraction

Published
2021

7. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis.

Author

Zlotoff, Daniel A, Hassan, Malek Z O, Zafar, Amna, Alvi, Raza M, Awadalla, Magid, Mahmood, Syed S, Zhang, Lili, Chen, Carol L, Ederhy, Stephane, Barac, Ana, Banerji, Dahlia, Jones-O'Connor, Maeve, Murphy, Sean P, Armanious, Merna, Forrestal, Brian J, Kirchberger, Michael C, Coelho-Filho, Otavio R, Rizvi, Muhammad A, Sahni, Gagan, Mandawat, Anant, Tocchetti, Carlo G, Hartmann, Sarah, Gilman, Hannah K, Zatarain-Nicolás, Eduardo, Mahmoudi, Michael, Gupta, Dipti, Sullivan, Ryan, Ganatra, Sarju, Yang, Eric H, Heinzerling, Lucie M, Thuny, Franck, Zubiri, Leyre, Reynolds, Kerry L, Cohen, Justine V, Lyon, Alexander R, Groarke, John, Thavendiranathan, Paaladinesh, Nohria, Anju, Fradley, Michael G, and Neilan, Tomas G

Abstract

Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI) use that remains inadequately characterized. The QRS duration and the QTc interval are standardized electrocardiographic measures that are prolonged in other cardiac conditions; however, there are no data on their utility in ICI myocarditis.From an international registry, ECG parameters were compared between 140 myocarditis cases and 179 controls across multiple time points (pre-ICI, on ICI prior to myocarditis, and at the time of myocarditis). The association between ECG values and major adverse cardiac events (MACE) was also tested.Both the QRS duration and QTc interval were similar between cases and controls prior to myocarditis. When compared with controls on an ICI (93±19 ms) or to baseline prior to myocarditis (97±19 ms), the QRS duration prolonged with myocarditis (110±22 ms, p

Published
2021

8. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor�Associated Myocarditis

Author

Zhang, Lili, Zlotoff, Daniel A, Awadalla, Magid, Mahmood, Syed S, Nohria, Anju, Hassan, Malek Z.O., Thuny, Franck, Zubiri, Leyre, Chen, Carol L, Sullivan, Ryan J, Alvi, Raza M, Rokicki, Adam, Murphy, Sean P, Jones-O’Connor, Maeve, Heinzerling, Lucie M, Barac, Ana, Forrestal, Brian J, Yang, Eric H, Gupta, Dipti, Kirchberger, Michael C, Shah, Sachin P, Rizvi, Muhammad A, Sahni, Gagan, Mandawat, Anant, Mahmoudi, Michael, Ganatra, Sarju, Ederhy, Stephane, Zatarain-Nicolas, Eduardo, Groarke, John D, Tocchetti, Carlo G, Lyon, Alexander R, Thavendiranathan, Paaladinesh, Cohen, Justine V, Reynolds, Kerry L, Fradley, Michael G, and Neilan, Tomas G

Published
2020

9. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.

Author

Zhang, Lili, Awadalla, Magid, Mahmood, Syed S, Nohria, Anju, Hassan, Malek Z O, Thuny, Franck, Zlotoff, Daniel A, Murphy, Sean P, Stone, James R, Golden, Doll Lauren Alexandra, Alvi, Raza M, Rokicki, Adam, Jones-O'Connor, Maeve, Cohen, Justine V, Heinzerling, Lucie M, Mulligan, Connor, Armanious, Merna, Barac, Ana, Forrestal, Brian J, Sullivan, Ryan J, Kwong, Raymond Y, Yang, Eric H, Damrongwatanasuk, Rongras, Chen, Carol L, Gupta, Dipti, Kirchberger, Michael C, Moslehi, Javid J, Coelho-Filho, Otavio R, Ganatra, Sarju, Rizvi, Muhammad A, Sahni, Gagan, Tocchetti, Carlo G, Mercurio, Valentina, Mahmoudi, Michael, Lawrence, Donald P, Reynolds, Kerry L, Weinsaft, Jonathan W, Baksi, A John, Ederhy, Stephane, Groarke, John D, Lyon, Alexander R, Fradley, Michael G, Thavendiranathan, Paaladinesh, and Neilan, Tomas G

Abstract

Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented.From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF ≥50%. Late gadolinium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort. Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26% of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology. Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of 5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE.These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-associated myocarditis.

Published
2020

10. Abstract 18186: Four Chambers Strain Analysis in Patients Admitted With Acute Heart Failure: A New Characterization of Heart Involvement?

Author

Soulat-Dufour, Laurie, Bourai, Ania, Lang, Sylvie, Capderou, Elodie, EDERHY, Stephane, ADAVANE, Saroumadi, Chauvet-Droit, Marion, Arnaud, Camille, Issaurat, Pauline, Jullien, Stéphanie, Cardoso, Chloé, Gerard, Manon, Cherif, Ghassen, Addetia, Karima, Boccara, Franck, Assyag, Patrick, Lang, Roberto, and Cohen, Ariel

Published
2023
Full Text
View/download PDF

11. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology.

Author

Bonaca, Marc, Olenchock, Benjamin, Salem, Joe-Elie, Wiviott, Stephen, Ederhy, Stephane, Cohen, Ariel, Stewart, Garrick, Choueiri, Toni, Di Carli, Marcelo, Allenbach, Yves, Kumbhani, Dharam, Heinzerling, Lucie, Amiri-Kordestani, Laleh, Lyon, Alexander, Thavendiranathan, Paaladinesh, Padera, Robert, Lichtman, Andrew, Liu, Peter, Johnson, Douglas, and Moslehi, Javid

Subjects
oncology, medical, adjudication, immunotherapy, cardiovascular disease, myocarditis, immunosuppressive agents, Antineoplastic Agents, Immunological, Cardiology, Clinical Trials as Topic, Humans, Immunotherapy, Medical Oncology, Myocarditis, Neoplasms
Abstract

Recent developments in cancer therapeutics have improved outcomes but have also been associated with cardiovascular complications. Therapies harnessing the immune system have been associated with an immune-mediated myocardial injury described as myocarditis. Immune checkpoint inhibitors are one such therapy with an increasing number of case and cohort reports describing a clinical syndrome of immune checkpoint inhibitor–associated myocarditis. Although the full spectrum of immune checkpoint inhibitor–associated cardiovascular disease still needs to be fully defined, described cases of myocarditis range from syndromes with mild signs and symptoms to fatal events. These observations in the clinical setting stand in contrast to outcomes from randomized clinical trials in which myocarditis is a rare event that is investigator reported and lacking in a specific case definition. The complexities associated with diagnosis, as well as the heterogeneous clinical presentation of immune checkpoint inhibitor–associated myocarditis, have made ascertainment and identification of myocarditis with high specificity challenging in clinical trials and other data sets, limiting the ability to better understand the incidence, outcomes, and predictors of these rare events. Therefore, establishing a uniform definition of myocarditis for application in clinical trials of cancer immunotherapies will enable greater understanding of these events. We propose an operational definition of cancer therapy-associated myocarditis that may facilitate case ascertainment and report and therefore may enhance the understanding of the incidence, outcomes, and risk factors of this novel clinical syndrome.

Published
2019

12. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.

Author

Awadalla, Magid, Golden, Doll, Mahmood, Syed, Alvi, Raza, Mercaldo, Nathaniel, Hassan, Malek, Banerji, Dahlia, Rokicki, Adam, Mulligan, Connor, Murphy, Sean, Jones-OConnor, Maeve, Cohen, Justine, Heinzerling, Lucie, Armanious, Merna, Sullivan, Ryan, Damrongwatanasuk, Rongras, Chen, Carol, Gupta, Dipti, Kirchberger, Michael, Moslehi, Javid, Shah, Sachin, Ganatra, Sarju, Thavendiranathan, Paaladinesh, Rizvi, Muhammad, Sahni, Gagan, Lyon, Alexander, Tocchetti, Carlo, Mercurio, Valentina, Thuny, Franck, Ederhy, Stephane, Mahmoudi, Michael, Lawrence, Donald, Groarke, John, Nohria, Anju, Fradley, Michael, Reynolds, Kerry, and Neilan, Tomas

Subjects
Cancer, Cardiovascular disease, Immune checkpoint inhibitors, Immune-related adverse events, Influenza vaccination, Major adverse cardiac events, Myocarditis, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Female, Humans, Influenza Vaccines, Influenza, Human, Male, Middle Aged, Myocarditis, Neoplasms, Registries, Vaccination
Abstract

BACKGROUND: Influenza vaccination (FV) is recommended for patients with cancer. Recent data suggested that the administration of the FV was associated with an increase in immune-related adverse events (irAEs) among patients on immune checkpoint inhibitors (ICIs). Myocarditis is an uncommon but serious complication of ICIs and may also result from infection with influenza. There are no data testing the relationship between FV and the development of myocarditis on ICIs. METHODS: Patients on ICIs who developed myocarditis (n = 101) (cases) were compared to ICI-treated patients (n = 201) without myocarditis (controls). A patient was defined as having the FV if they were administered the FV from 6 months prior to start of ICI to anytime during ICI therapy. Alternate thresholds for FV status were also tested. The primary comparison of interest was the rate of FV between cases and controls. Patients with myocarditis were followed for major adverse cardiac events (MACE), defined as the composite of cardiogenic shock, cardiac arrest, hemodynamically significant complete heart block and cardiovascular death. RESULTS: The FV was administered to 25% of the myocarditis cases compared to 40% of the non-myocarditis ICI-treated controls (p = 0.01). Similar findings of lower rates of FV administration were noted among myocarditis cases when alternate thresholds were tested. Among the myocarditis cases, those who were vaccinated had 3-fold lower troponin levels when compared to unvaccinated cases (FV vs. No FV: 0.12 [0.02, 0.47] vs. 0.40 [0.11, 1.26] ng/ml, p = 0.02). Within myocarditis cases, those administered the FV also had a lower rate of other irAEs when compared to unvaccinated cases (36 vs. 55% p = 0.10) including lower rates of pneumonitis (12 vs. 36%, p = 0.03). During follow-up (175 [IQR 89, 363] days), 47% of myocarditis cases experienced a MACE. Myocarditis cases who received the FV were at a lower risk of cumulative MACE when compared to unvaccinated cases (24 vs. 59%, p = 0.002). CONCLUSION: The rate of FV among ICI-related myocarditis cases was lower than controls on ICIs who did not develop myocarditis. In those who developed myocarditis related to an ICI, there was less myocardial injury and a lower risk of MACE among those who were administered the FV.

Published
2019

13. Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

Author

Quinaglia, Thiago, Gongora, Carlos, Awadalla, Magid, Hassan, Malek Z.O., Zafar, Amna, Drobni, Zsofia D., Mahmood, Syed S., Zhang, Lili, Coelho-Filho, Otavio R., Suero-Abreu, Giselle A., Rizvi, Muhammad A., Sahni, Gagan, Mandawat, Anant, Zatarain-Nicolás, Eduardo, Mahmoudi, Michael, Sullivan, Ryan, Ganatra, Sarju, Heinzerling, Lucie M., Thuny, Franck, Ederhy, Stephane, Gilman, Hannah K., Sama, Supraja, Nikolaidou, Sofia, Mansilla, Ana González, Calles, Antonio, Cabral, Marcella, Fernández-Avilés, Francisco, Gavira, Juan José, González, Nahikari Salterain, García de Yébenes Castro, Manuel, Barac, Ana, Afilalo, Jonathan, Zlotoff, Daniel A., Zubiri, Leyre, Reynolds, Kerry L., Devereux, Richard, Hung, Judy, Picard, Michael H., Yang, Eric H., Gupta, Dipti, Michel, Caroline, Lyon, Alexander R., Chen, Carol L., Nohria, Anju, Fradley, Michael G., Thavendiranathan, Paaladinesh, and Neilan, Tomas G.

Published
2022
Full Text
View/download PDF

15. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis

Author

Fenioux, Charlotte, Abbar, Baptiste, Allenbach, Yves, Crusz, Shanthini M., Ghosh, Arjun K., Moran, Tyler, Mehegan, Tyler, Piro, Lawrence, Chang, Wei-Ting, Chahine, Johnny, Flint, Danette, Stringer, Ben, Gounant, Valérie, Nicol, Martin, Baroudjian, Barouyr, Zimmer, Marie-Claire, Mervoyer, Elvire, Leong, Darryl, Morimoto, Ryota, Piriou, Nicolas, Monge, Cecilia, Copeland, Amy, Ghafourian, Kambiz, Guha, Avirup, Brodsky, Sergey, Ben Zadok, Osnat Itzhaki, Habib, Manhal, Dy, Grace, Warner, Ellen, Laufer-Perl, Michal, Koo Lin, Lily, Narezkina, Ana, Baik, Alan, Lenneman, Carrie, Vachhani, Pankit, Azam, Tariq U., Perry, Daniel, Blakely, Pennelope, Tajiri, Kazuko, Martini, Matthew, Nowatzke, Joseph, Orimoloye, Olusola Ayodeji, Hughes, Andrew, Baldassarre, Lauren A., Patel, Milan, Power, John R., Alexandre, Joachim, Choudhary, Arrush, Ozbay, Benay, Hayek, Salim S., Asnani, Aarti, Tamura, Yuichi, Aras, Mandar, Cautela, Jennifer, Thuny, Franck, Gilstrap, Lauren, Arangalage, Dimitri, Ewer, Steven, Huang, Shi, Deswal, Anita, Palaskas, Nicolas L., Finke, Daniel, Lehmann, Lorenz H., Ederhy, Stephane, Moslehi, Javid, and Salem, Joe-Elie

Published
2022
Full Text
View/download PDF

16. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation

Author

Duléry, Rémy, Mohty, Razan, Labopin, Myriam, Sestili, Simona, Malard, Florent, Brissot, Eolia, Battipaglia, Giorgia, Médiavilla, Clémence, Banet, Anne, Van de Wyngaert, Zoé, Paviglianiti, Annalisa, Belhocine, Ramdane, Isnard, Françoise, Lapusan, Simona, Adaeva, Rosa, Vekhoff, Anne, Ledraa, Tounes, Legrand, Ollivier, Cohen, Ariel, Bonnin, Agnès, Ederhy, Stéphane, and Mohty, Mohamad

Published
2021
Full Text
View/download PDF

21. Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care Protocol)

Author

Fiot, Elodie, Alauze, Bertille, Donadille, Bruno, Samara-Boustani, Dinane, Houang, Muriel, De Filippo, Gianpaolo, Bachelot, Anne, Delcour, Clemence, Beyler, Constance, Bois, Emilie, Bourrat, Emmanuelle, Bui Quoc, Emmanuel, Bourcigaux, Nathalie, Chaussain, Catherine, Cohen, Ariel, Cohen-Solal, Martine, Da Costa, Sabrina, Dossier, Claire, Ederhy, Stephane, Elmaleh, Monique, Iserin, Laurence, Lengliné, Hélène, Poujol-Robert, Armelle, Roulot, Dominique, Viala, Jerome, Albarel, Frederique, Bismuth, Elise, Bernard, Valérie, Bouvattier, Claire, Brac, Aude, Bretones, Patricia, Chabbert-Buffet, Nathalie, Chanson, Philippe, Coutant, Regis, de Warren, Marguerite, Demaret, Béatrice, Duranteau, Lise, Eustache, Florence, Gautheret, Lydie, Gelwane, Georges, Gourbesville, Claire, Grynberg, Mickaël, Gueniche, Karinne, Jorgensen, Carina, Kerlan, Veronique, Lebrun, Charlotte, Lefevre, Christine, Lorenzini, Françoise, Manouvrier, Sylvie, Pienkowski, Catherine, Reynaud, Rachel, Reznik, Yves, Siffroi, Jean-Pierre, Tabet, Anne-Claude, Tauber, Maithé, Vautier, Vanessa, Tauveron, Igor, Wambre, Sebastien, Zenaty, Delphine, Netchine, Irène, Polak, Michel, Touraine, Philippe, Carel, Jean-Claude, Christin-Maitre, Sophie, and Léger, Juliane

Published
2022
Full Text
View/download PDF

22. In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort

Author

Ederhy, Stephane, Cohen, Ariel, Boccara, Franck, Puymirat, Etienne, Aissaoui, Nadia, Elbaz, Meyer, Bonnefoy-Cudraz, Eric, Druelles, Philipe, Andrieu, Stephane, Angoulvant, Denis, Furber, Alain, Ferrières, Jean, Schiele, François, Cottin, Yves, Simon, Tabassome, and Danchin, Nicolas

Published
2019
Full Text
View/download PDF

25. Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis

Author

Power, John R., Alexandre, Joachim, Choudhary, Arrush, Ozbay, Benay, Hayek, Salim, Asnani, Aarti, Tamura, Yuichi, Aras, Mandar, Cautela, Jennifer, Thuny, Franck, Gilstrap, Lauren, Arangalage, Dimitri, Ewer, Steven, Huang, Shi, Deswal, Anita, Palaskas, Nicolas L., Finke, Daniel, Lehman, Lorenz, Ederhy, Stephane, Moslehi, Javid, and Salem, Joe-Elie

Published
2021
Full Text
View/download PDF

28. Abstract 15146: Reverse Right Heart Chambers Remodeling and Decrease in Tricuspid Regurgitation Severity After Restoration of Sinus Rhythm in Patients With Atrial Fibrillation: A Mid-term 3d Echocardiographic Study

Author

Benhamou Tarallo, Iris, SOULAT-DUFOUR, Laurie, Lang, Sylvie, Ederhy, Stephane, Adavane-Scheuble, Saroumadi, Chauvet-Droit, Marion, Nhan, Pascal, Jean, Marie-Liesse, Ben Said, Rim, Issaurat, Pauline, Boccara, Franck, and Cohen, Ariel A

Published
2020
Full Text
View/download PDF

29. Abstract 14843: Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Associated Myocarditis

Author

Power, John R, Alexandre, Joachim, Choudhary, Arrush, ozbay, benay, Palaskas, Nicolas L, Lehmann, Lorenz H, Finke, Daniel, Cautela, Jennifer, Thuny, Franck, Tamura, Yuichi, Hayek, Salim S, Azam, Tariq U, Asnani, Aarti, Mehegan, Tyler, Aras, Mandar A, Baik, Alan H, Gilstrap, Lauren, Laufer-Perl, Michal, Arangalage, Dimitri, Ewer, Steven, Martini, Matthew, Nowatzke, Joseph, Orimoloye, Olusola A, Brinkley, Douglas M, Meijers, Wouter C, Fenioux, Charlotte, EDERHY, Stephane, Moslehi, Javid J, and Salem, Joe-elie

Published
2020
Full Text
View/download PDF

30. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis

Author

Zhang, Lili, Zlotoff, Daniel A., Awadalla, Magid, Mahmood, Syed S., Nohria, Anju, Hassan, Malek Z.O., Thuny, Franck, Zubiri, Leyre, Chen, Carol L., Sullivan, Ryan J., Alvi, Raza M., Rokicki, Adam, Murphy, Sean P., Jones-O’Connor, Maeve, Heinzerling, Lucie M., Barac, Ana, Forrestal, Brian J., Yang, Eric H., Gupta, Dipti, Kirchberger, Michael C., Shah, Sachin P., Rizvi, Muhammad A., Sahni, Gagan, Mandawat, Anant, Mahmoudi, Michael, Ganatra, Sarju, Ederhy, Stephane, Zatarain-Nicolas, Eduardo, Groarke, John D., Tocchetti, Carlo G., Lyon, Alexander R., Thavendiranathan, Paaladinesh, Cohen, Justine V., Reynolds, Kerry L., Fradley, Michael G., and Neilan, Tomas G.

Published
2020
Full Text
View/download PDF

31. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

Author

Coustal, Cyrille, primary, Vanoverschelde, Juliette, additional, Quantin, Xavier, additional, Lesage, Candice, additional, Michot, Jean-Marie, additional, Lappara, Ariane, additional, Ederhy, Stephane, additional, Assenat, Eric, additional, Faure, Maxime, additional, Issa, Nahema, additional, Lambotte, Olivier, additional, Puyade, Mathieu, additional, Dereure, Olivier, additional, Tosi, Diego, additional, Rullier, Patricia, additional, Serre, Isabelle, additional, Larcher, Romaric, additional, Klouche, Kada, additional, Chanques, Gérald, additional, Vernhet-Kovacsik, Hélène, additional, Faillie, Jean-Luc, additional, Agullo, Audrey, additional, Roubille, François, additional, Guilpain, Philippe, additional, and Maria, Alexandre Thibault Jacques, additional

Published
2023
Full Text
View/download PDF

32. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.

Author

Salem, Joe-Elie, Salem, Joe-Elie, Bretagne, Marie, Abbar, Baptiste, Leonard-Louis, Sarah, Ederhy, Stephane, Redheuil, Alban, Boussouar, Samia, Nguyen, Lee S, Procureur, Adrien, Stein, Frederic, Fenioux, Charlotte, Devos, Perrine, Gougis, Paul, Dres, Martin, Demoule, Alexandre, Psimaras, Dimitri, Lenglet, Timothee, Maisonobe, Thierry, Pineton DE Chambrun, Marc, Hekimian, Guillaume, Straus, Christian, Gonzalez-Bermejo, Jesus, Klatzmann, David, Rigolet, Aude, Guillaume-Jugnot, Perrine, Champtiaux, Nicolas, Benveniste, Olivier, Weiss, Nicolas, Saheb, Samir, Rouvier, Philippe, Plu, Isabelle, Gandjbakhch, Estelle, Kerneis, Mathieu, Hammoudi, Nadjib, Zahr, Noel, Llontop, Claudia, Morelot-Panzini, Capucine, Lehmann, Lorenz, Qin, Juan, Moslehi, Javid J, Rosenzwajg, Michelle, Similowski, Thomas, Allenbach, Yves, Salem, Joe-Elie, Salem, Joe-Elie, Bretagne, Marie, Abbar, Baptiste, Leonard-Louis, Sarah, Ederhy, Stephane, Redheuil, Alban, Boussouar, Samia, Nguyen, Lee S, Procureur, Adrien, Stein, Frederic, Fenioux, Charlotte, Devos, Perrine, Gougis, Paul, Dres, Martin, Demoule, Alexandre, Psimaras, Dimitri, Lenglet, Timothee, Maisonobe, Thierry, Pineton DE Chambrun, Marc, Hekimian, Guillaume, Straus, Christian, Gonzalez-Bermejo, Jesus, Klatzmann, David, Rigolet, Aude, Guillaume-Jugnot, Perrine, Champtiaux, Nicolas, Benveniste, Olivier, Weiss, Nicolas, Saheb, Samir, Rouvier, Philippe, Plu, Isabelle, Gandjbakhch, Estelle, Kerneis, Mathieu, Hammoudi, Nadjib, Zahr, Noel, Llontop, Claudia, Morelot-Panzini, Capucine, Lehmann, Lorenz, Qin, Juan, Moslehi, Javid J, Rosenzwajg, Michelle, Similowski, Thomas, and Allenbach, Yves

Abstract

Immune-checkpoint-inhibitor (ICI)-associated myotoxicity involves the heart (myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and is highly fatal. We report the results of a strategy that included identification of individuals with severe ICI-myocarditis by also screening for and managing concomitant respiratory muscle involvement with mechanical ventilation, as well as treatment with CTLA4-fusion protein abatacept and the Janus-kinase inhibitor ruxolitinib. Forty cases with definite ICI-myocarditis were included with pathological confirmation of concomitant myositis in the majority of patients. In the first 10 patients, using recommended guidelines, myotoxicity-related fatality occurred in 60%, consistent with historical controls. In the subsequent 30 cases, we instituted systematic screening for respiratory muscle involvement coupled with active ventilation and treatment using ruxolitinib and abatacept. Abatacept dose was adjusted using CD86-receptor occupancy on circulating monocytes. Myotoxicity-related fatality rate was 3.4%(1/30) in these 30 patients vs.60% in 1st quartile(p<0.0001). These clinical results are hypothesis-generating and need further evaluation.

Published
2023

33. 2023 ESC Guidelines for the management of endocarditis

Author

Delgado, V, Ajmone Marsan, N, de Waha, S, Bonaros, N, Brida, M, Burri, H, Caselli, S, Doenst, T, Ederhy, S, Erba, P, Foldager, D, Fosbøl, E, Kovac, J, Mestres, C, Miller, O, Miro, J, Pazdernik, M, Pizzi, M, Quintana, E, Rasmussen, T, Ristić, A, Rodés-Cabau, J, Sionis, A, Zühlke, L, Borger, M, Delgado, Victoria, Ajmone Marsan, Nina, de Waha, Suzanne, Bonaros, Nikolaos, Brida, Margarita, Burri, Haran, Caselli, Stefano, Doenst, Torsten, Ederhy, Stephane, Erba, Paola Anna, Foldager, Dan, Fosbøl, Emil L, Kovac, Jan, Mestres, Carlos A, Miller, Owen I, Miro, Jose M, Pazdernik, Michal, Pizzi, Maria Nazarena, Quintana, Eduard, Rasmussen, Trine Bernholdt, Ristić, Arsen D, Rodés-Cabau, Josep, Sionis, Alessandro, Zühlke, Liesl Joanna, Borger, Michael A, Delgado, V, Ajmone Marsan, N, de Waha, S, Bonaros, N, Brida, M, Burri, H, Caselli, S, Doenst, T, Ederhy, S, Erba, P, Foldager, D, Fosbøl, E, Kovac, J, Mestres, C, Miller, O, Miro, J, Pazdernik, M, Pizzi, M, Quintana, E, Rasmussen, T, Ristić, A, Rodés-Cabau, J, Sionis, A, Zühlke, L, Borger, M, Delgado, Victoria, Ajmone Marsan, Nina, de Waha, Suzanne, Bonaros, Nikolaos, Brida, Margarita, Burri, Haran, Caselli, Stefano, Doenst, Torsten, Ederhy, Stephane, Erba, Paola Anna, Foldager, Dan, Fosbøl, Emil L, Kovac, Jan, Mestres, Carlos A, Miller, Owen I, Miro, Jose M, Pazdernik, Michal, Pizzi, Maria Nazarena, Quintana, Eduard, Rasmussen, Trine Bernholdt, Ristić, Arsen D, Rodés-Cabau, Josep, Sionis, Alessandro, Zühlke, Liesl Joanna, and Borger, Michael A

Published
2023

34. 2023 ESC Guidelines for the management of endocarditis:Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)

Author

Delgado, Victoria, Ajmone Marsan, Nina, De Waha, Suzanne, Bonaros, Nikolaos, Brida, Margarita, Burri, Haran, Caselli, Stefano, Doenst, Torsten, Ederhy, Stephane, Erba, Paola Anna, Foldager, Dan, Fosbøl, Emil L., Kovac, Jan, Mestres, Carlos A., Miller, Owen I., Miro, Jose M., Pazdernik, Michal, Pizzi, Maria Nazarena, Quintana, Eduard, Rasmussen, Trine Bernholdt, Ristić, Arsen D., Rodes-Cabau, Josep, Sionis, Alessandro, Zühlke, Liesl Joanna, Borger, Michael A., Delgado, Victoria, Ajmone Marsan, Nina, De Waha, Suzanne, Bonaros, Nikolaos, Brida, Margarita, Burri, Haran, Caselli, Stefano, Doenst, Torsten, Ederhy, Stephane, Erba, Paola Anna, Foldager, Dan, Fosbøl, Emil L., Kovac, Jan, Mestres, Carlos A., Miller, Owen I., Miro, Jose M., Pazdernik, Michal, Pizzi, Maria Nazarena, Quintana, Eduard, Rasmussen, Trine Bernholdt, Ristić, Arsen D., Rodes-Cabau, Josep, Sionis, Alessandro, Zühlke, Liesl Joanna, and Borger, Michael A.

Published
2023

38. 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)

Author

Delgado, Victoria, Marsan, Nina Ajmone, Waha, Suzanne de, Bonaros, Nikolaos, Brida, Margarita, Burri, Haran, Caselli, Stefano, Doenst, Torsten, Ederhy, Stephane, Erba, Paola Anna, Foldager, Dan, Fosbøl, Emil L, Kovac, Jan, Mestres, Carlos A, Miller, Owen I, Miro, Jose M, Pazdernik, Michal, Pizzi, Maria Nazarena, Quintana, Eduard, and Rasmussen, Trine Bernholdt

Subjects
ENTEROCOCCAL infections, SEX factors in disease, SINGLE-photon emission computed tomography, POSITRON emission tomography computed tomography, TASK forces, ENDOCARDITIS
Abstract

Overall, the incidence of osteoarticular infection among patients with IE is 6-8%, including bones, joints, and vertebral discs.[5],[145],[247],[516] The prevalence of spondylodiscitis ranges from 2% to 10% in patients with IE, including symptomatic and asymptomatic cases,[248],[517] while series of spontaneous spondylodiscitis have reported co-existing IE in up to 20-30% of patients.[[518], [520]] In general, the rate of IE is 10 times higher in patients with known spondylodiscitis. Patients with neutropaenia Neutropaenia is common in patients with haematological malignancies and in patients receiving chemotherapy for other malignancies, but is rare in patients presenting with IE.[814] Neutrophils play an important role in the pathogenesis of IE by producing layers of extracellular traps that entrap bacteria-platelet aggregates, leading to expansion of these aggregates, vegetation growth, and the destruction of tissues.[814] The diagnosis of IE can therefore be challenging in patients with neutropaenia, delaying the appropriate treatment, and worsening outcomes. Patient-centred care encourages involvement and collaboration between patients, families, and healthcare providers during all stages of diagnosis, treatment, and recovery.[[828], [830]] Core elements of patient-centred care include: involvement of family and caregivers, respect for patients' preferences and values, care co-ordination and continuity, information and education, as well as physical comfort and emotional support ( I Figure 14 i ).[[828], [830]] Graph: Figure 14 Concept of patient-centred care in infective endocarditis. [Extracted from the article]

Published
2023
Full Text
View/download PDF

40. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity

Author

Escudier, Marion, Cautela, Jennifer, Malissen, Nausicaa, Ancedy, Yann, Orabona, Morgane, Pinto, Johan, Monestier, Sandrine, Grob, Jean-Jacques, Scemama, Ugo, Jacquier, Alexis, Lalevee, Nathalie, Barraud, Jeremie, Peyrol, Michael, Laine, Marc, Bonello, Laurent, Paganelli, Franck, Cohen, Ariel, Barlesi, Fabrice, Ederhy, Stephane, and Thuny, Franck

Published
2017
Full Text
View/download PDF

41. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis

Author

Power, John R., primary, Alexandre, Joachim, additional, Choudhary, Arrush, additional, Ozbay, Benay, additional, Hayek, Salim S., additional, Asnani, Aarti, additional, Tamura, Yuichi, additional, Aras, Mandar, additional, Cautela, Jennifer, additional, Thuny, Franck, additional, Gilstrap, Lauren, additional, Arangalage, Dimitri, additional, Ewer, Steven, additional, Huang, Shi, additional, Deswal, Anita, additional, Palaskas, Nicolas L., additional, Finke, Daniel, additional, Lehmann, Lorenz H., additional, Ederhy, Stephane, additional, Moslehi, Javid, additional, Salem, Joe-Elie, additional, Fenioux, Charlotte, additional, Abbar, Baptiste, additional, Allenbach, Yves, additional, Crusz, Shanthini M., additional, Ghosh, Arjun K., additional, Moran, Tyler, additional, Mehegan, Tyler, additional, Piro, Lawrence, additional, Chang, Wei-Ting, additional, Chahine, Johnny, additional, Flint, Danette, additional, Stringer, Ben, additional, Gounant, Valérie, additional, Nicol, Martin, additional, Baroudjian, Barouyr, additional, Zimmer, Marie-Claire, additional, Mervoyer, Elvire, additional, Leong, Darryl, additional, Morimoto, Ryota, additional, Piriou, Nicolas, additional, Monge, Cecilia, additional, Copeland, Amy, additional, Ghafourian, Kambiz, additional, Guha, Avirup, additional, Brodsky, Sergey, additional, Ben Zadok, Osnat Itzhaki, additional, Habib, Manhal, additional, Dy, Grace, additional, Warner, Ellen, additional, Laufer-Perl, Michal, additional, Koo Lin, Lily, additional, Narezkina, Ana, additional, Baik, Alan, additional, Lenneman, Carrie, additional, Vachhani, Pankit, additional, Azam, Tariq U., additional, Perry, Daniel, additional, Blakely, Pennelope, additional, Tajiri, Kazuko, additional, Martini, Matthew, additional, Nowatzke, Joseph, additional, Orimoloye, Olusola Ayodeji, additional, Hughes, Andrew, additional, Baldassarre, Lauren A., additional, and Patel, Milan, additional

Published
2022
Full Text
View/download PDF

42. Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19

Author

Salem, Joe-Elie, Hammoudi, Nadjib, Pinna, Bruno, Ederhy, Stephane, Lamazière, Antonin, Fenioux, Charlotte, Redheuil, Alban, Salem, Pierre, Ribet, Claire, Hamwy, Omar, Marcelin, Anne-Geneviève, Burrel, Sonia, Funck-Brentano, Christian, Montalescot, Gilles, Lacorte, Jean-Marc, Gandjbakhch, Estelle, Benveniste, Olivier, Saadoun, David, Allenbach, Yves, Boussouar, Samia, Prifti, Edi, and Cacoub, Patrice

Published
2022
Full Text
View/download PDF

45. Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation

Author

Soulat-Dufour, Laurie, primary, Lang, Sylvie, additional, Addetia, Karima, additional, Ederhy, Stephane, additional, Adavane-Scheuble, Saroumadi, additional, Chauvet-Droit, Marion, additional, Jean, Marie-Liesse, additional, Nhan, Pascal, additional, Ben Said, Rim, additional, Kamami, Iris, additional, Issaurat, Pauline, additional, Capderou, Elodie, additional, Arnaud, Camille, additional, Boccara, Franck, additional, Lang, Roberto M., additional, and Cohen, Ariel, additional

Published
2022
Full Text
View/download PDF

46. Interaction entre échocardiographie et système rénine-aldostérone comme prédicteurs de mortalité pour le COVID-19

Author

Salem, Joe-Elie, Hammoudi, Nadjib, Pinna, Bruno, Ederhy, Stephane, Lamazière, Antonin, Fenioux, Charlotte, Redheuil, Alban, Salem, Pierre, Ribet, Claire, Hamwy, Omar, Marcelin, Anne-Geneviève, Burrel, Sonia, Funck-Brentano, Christian, Montalescot, Gilles, Lacorte, Jean-Marc, Gandjbakhch, Estelle, Benveniste, Olivier, Saadoun, David, Allenbach, Yves, Boussouar, Samia, Prifti, Edi, Cacoub, Patrice, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] (CIC Paris-Est), Centre d'investigation clinique pluridisciplinaire [CHU Pitié Salpêtrière] (CIC-P 1421), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Saint-Antoine [AP-HP], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de recherche en Myologie – U974 SU-INSERM, Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] (UMMISCO), and Université de Yaoundé I-Institut de la francophonie pour l'informatique-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Gaston Bergé (Saint-Louis, Sénégal)-Université Cadi Ayyad [Marrakech] (UCA)-Sorbonne Université (SU)-Institut de Recherche pour le Développement (IRD [France-Nord])

Subjects
Biomarqueurs, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Echocardiography, Aldostérone, COVID-19, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Échocardiographie, Prognosis, Aldosterone, ComputingMilieux_MISCELLANEOUS, Biomarkers
Abstract

International audience

Published
2022
Full Text
View/download PDF

48. Transesophageal echocardiography for cardiovascular risk estimation in patients with sepsis and new-onset atrial fibrillation: a multicenter prospective pilot study

Author

Labbé, Vincent, Ederhy, Stephane, Lapidus, Nathanael, Joffre, Jérémie, Razazi, Keyvan, Laine, Laurent, Sy, Oumar, Voicu, Sebastian, Chemouni, Frank, Aissaoui, Nadia, Smonig, Roland, Doyen, Denis, Carrat, Fabrice, Voiriot, Guillaume, Mekontso-Dessap, Armand, Cohen, Ariel, Fartoukh, Muriel, Guidet, Bertrand, Ait-Oufella, Hafid, Bourcier, Simon, da Silva, Daniel, Jochmans, Sebastien, Dellamonica, Jean, Timsit, Jean-François, Megarbane, Bruno, Diehl, Jean-Luc, Rushton-Smith, Sophie, Service de Réanimation et USC Médico-Chirurgicale = Médecine intensive réanimation [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de recherche clinique CARMAS (Cardiovascular and Respiratory Manifestations of Acute lung injury and Sepsis) (CARMAS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Henri Mondor, Département Médico-Universitaire APPROCHES, Service de Cardiologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Thrombose, atherothrombose et pharmacologie appliquée, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de santé publique [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de Réanimation Médicale [CHU Saint-Antoine], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier de Saint-Denis [Ile-de-France], Centre Hospitalier de Melun (CHM), Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Gustave Roussy (IGR), Département d'anesthésie, réanimation et pathologie infectieuse (DARPI), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Universitaire de Nice (CHU Nice), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [IHU ICAN], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), HAL-SU, Gestionnaire, Service de Réanimation et USC Médico-Chirurgicale [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor, Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de Melun, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Groupe Henri Mondor-Albert Chenevier, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Université Paris Descartes - Paris 5 (UPD5), Unité de Recherche Clinique de la Côte d’Azur [Nice] (URRIS UR2CA), Université Côte d'Azur (UCA), Sorbonne Université - Faculté de Médecine (SU FM), FAST Study Group: Bertrand Guidet, Hafid Ait-Oufella, Simon Bourcier, Daniel Da Silva, Sebastien Jochmans, Jean Dellamonica, Jean-François Timsit, Bruno Megarbane, Jean-Luc Diehl, Sophie Rushton-Smith, and WEISS, Nicolas

Subjects
medicine.medical_specialty, [SDV]Life Sciences [q-bio], Atrial fibrillation Transesophageal echocardiography Stroke Bleeding Sepsis, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, Sepsis, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Anesthesiology, medicine, 030212 general & internal medicine, cardiovascular diseases, Thrombus, Transesophageal echocardiography, Stroke, RC86-88.9, business.industry, Septic shock, Research, Incidence (epidemiology), Hazard ratio, Bleeding, Medical emergencies. Critical care. Intensive care. First aid, Atrial fibrillation, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], Cardiology, cardiovascular system, business
Abstract

Background Echocardiographic parameters have been poorly investigated for estimating cardiovascular risk in patients with sepsis and new-onset atrial fibrillation. We aim to assess the prevalence of transesophageal echocardiographic abnormalities and their relationship with cardiovascular events in mechanically ventilated patients with sepsis and new-onset atrial fibrillation. Methods In this prospective multicenter pilot study, left atrial/left atrial appendage (LA/LAA) dysfunction, severe aortic atheroma, and left ventricular systolic dysfunction were assessed using an initial transesophageal echocardiographic study, which was repeated after 48–72 h to detect LA/LAA thrombus formation. The study outcome was a composite of cardiovascular events at day 28, including arterial thromboembolic events (ischemic stroke, non-cerebrovascular arterial thromboembolism, LA/LAA thrombus), major bleeding, and all-cause death. Results The study population comprised 94 patients (septic shock 63%; 35% women; median age 69 years). LA/LAA dysfunction, severe aortic atheroma, and left ventricular systolic dysfunction were detected in 17 (19%), 22 (24%), and 27 (29%) patients, respectively. At day 28, the incidence of cardiovascular events was 46% (95% confidence interval [CI]: 35 to 56). Arterial thromboembolic events and major bleeding occurred in 7 (7%) patients (5 ischemic strokes, 1 non-cerebrovascular arterial thromboembolism, 2 left atrial appendage thrombi) and 18 (19%) patients, respectively. At day 28, 27 patients (29%) died. Septic shock (hazard ratio [HR]: 2.36; 95% CI 1.06 to 5.29) and left ventricular systolic dysfunction (HR: 2.06; 95% CI 1.05 to 4.05) were independently associated with cardiovascular events. Conclusions Transesophageal echocardiographic abnormalities are common in mechanically ventilated patients with sepsis and new-onset atrial fibrillation, but only left ventricular systolic dysfunction was associated with cardiovascular events at day 28.

Published
2021
Full Text
View/download PDF

49. Abstract 11777: Global Radial Strain Predicts Cardiovascular Events in Patients With Myocarditis Related to the Use of Immune Checkpoint Inhibitors

Author

Silva, Thiago, primary, Awadalla, Magid, additional, Hassan, Malek, additional, Zafar, Amna, additional, Drobni, Zsofia, additional, Gongora, Carlos, additional, Mahmood, Syed S, additional, Zhang, Lili, additional, Chen, Carol, additional, EDERHY, Stephane, additional, Barac, Ana, additional, Jones-O'Connor, Maeve, additional, Murphy, Sean, additional, Coelho-filho, Otavio R, additional, Rizvi, Muhammad, additional, SAHNI, GAGAN, additional, Carlo Gabriele, Tocchetti G, additional, Hartmann, Sarah, additional, Gilman, Hannah, additional, Zatarain-Nicolás, Eduardo, additional, Mahmoudi, Michael, additional, Gupta, Dipti, additional, Michel, Caroline, additional, Mansilla, Ana Gonzalez, additional, Calles, Antonio, additional, Cabral, Marcella, additional, Fernandez-Aviles, Francisco, additional, Gavira, Juan Jose, additional, Gonzalez, Nahikari S, additional, Garcia de Yebenes Castro, Manuel Y, additional, Afilalo, Jonathan, additional, Sullivan, Ryan, additional, Ganatra, Sarju, additional, Zlotoff, Daniel, additional, Yang, Eric, additional, Heinzerling, Lucie, additional, Thuny, Franck, additional, Zubiri, Leyre, additional, Reynolds, Kerry, additional, Lyon, Alexander, additional, Fradley, Michael, additional, Thavendiranathan, Paaladinesh, additional, and Neilan, Tomas, additional

Published
2021
Full Text
View/download PDF

50. Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries

Author

Debiec, Hanna, Dossier, Claire, Letouzé, Eric, Gillies, Christopher, Vivarelli, Marina, Putler, Rosemary, Ars, Elisabet, Jacqz-Aigrain, Evelyne, Elie, Valery, Colucci, Manuela, Debette, Stéphanie, Amouyel, Philippe, Elalaoui, Siham, Sefiani, Abdelaziz, Dubois, Valérie, Kretzler, Matthias, Ballarin, Jose, Emma, Francesco, Sampson, Matthew, Deschênes, Georges, Ronco, Pierre, Ederhy, Stephane, Cohen, Ariel, Boccara, Franck, Aissaoui, Nadia, Elbaz, Meyer, Bonnefoy-Cudraz, Eric, Druelles, Philipe, Andrieu, Stéphane, Angoulvant, Denis, Furber, Alain, Cottin, Yves, Puymirat, Etienne, Bonaca, Marc, Iliou, Marie-Christine, Tea, Victoria, Ducrocq, Grégory, Douard, Hervé, Labrunee, Marc, Plastaras, Philoktimon, Chevallereau, Pierre, Taldir, Guillaume, Bataille, Vincent, Ferrières, Jean, Schiele, François, Simon, Tabassome, Danchin, Nicolas, Centre de Ressources Biologiques APHP-SU (PASS-CRB-APHP-SU), Unité Mixte de Service Production et Analyse de données en Sciences de la vie et en Santé (PASS), and Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Time Factors, MESH: Registries, health care facilities, manpower, and services, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Cardiac rehabilitation, 030204 cardiovascular system & hematology, MESH: Risk Assessment, MESH: Aged, 80 and over, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Medicine, Registries, MESH: Cardiac Rehabilitation, 030212 general & internal medicine, Myocardial infarction, Atherothrombotic risk stratification, Non-ST Elevated Myocardial Infarction, health care economics and organizations, Cancer, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, education.field_of_study, MESH: Middle Aged, Framingham Risk Score, Rehabilitation, nephrotic syndrome, MESH: Polymorphism, Single Nucleotide, Hazard ratio, Score, genetic renal disease, General Medicine, Middle Aged, MESH: Recovery of Function, 3. Good health, In-hospital mortality, Treatment Outcome, Stratification risque athérothrombotique, cardiovascular system, Female, France, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, pediatrics, education, Population, Infarctus du myocarde, Acute myocardial infarction, Mortalité, MESH: Phenotype, Risk Assessment, 03 medical and health sciences, Intensive care, Internal medicine, MESH: Spain, Humans, cardiovascular diseases, Mortality, Réadaptation cardiaque, MESH: ST Elevation Myocardial Infarction, Medical prescription, Aged, focal segmental glomerulosclerosis, genome-wide association study, MESH: Humans, business.industry, MESH: Time Factors, MESH: Italy, Recovery of Function, medicine.disease, MESH: Male, MESH: Quantitative Trait Loci, MESH: Steroids, Confidence interval, MESH: France, MESH: Non-ST Elevated Myocardial Infarction, gene expression, Mortalité hospitalière, ST Elevation Myocardial Infarction, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Nephrotic Syndrome, business, MESH: Female
Abstract

Cardiac rehabilitation is strongly recommended in patients after acute myocardial infarction.To assess cardiac rehabilitation prescription after acute myocardial infarction according to predicted risk, and its association with 1-year mortality, using the FAST-MI registries.We used data from three 1-month French nationwide registries, conducted 5 years apart from 2005 to 2015, including 13130 patients with acute myocardial infarction admitted to coronary or intensive care units. Atherothrombotic risk stratification was performed using the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P). Patients were classified into three categories: Group 1 (low risk; no or one risk indicator; score of 0 or 1); Group 2 (intermediate risk; two risk indicators; score of 2); and Group 3 (high risk; at least three risk indicators; score of≥3).Among the 12291 patients, cardiac rehabilitation prescription was 43.6% (49.9% in Group 1; 43.0% in Group 2; 35.2% in Group 3). Using Cox multivariable analysis, cardiac rehabilitation prescription was associated with lower mortality at 1 year in the overall population (3.8% vs. 8.2%; hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.61-0.85; P0.001). Cardiac rehabilitation was associated with improved 1-year mortality, with homogeneous relative risk reductions in low- and intermediate-risk categories (HR 0.70, 95% CI 0.51-0.94) compared with high-risk patients (HR 0.72, 95% CI 0.59-0.88). In absolute terms, however, mortality decrease associated with cardiac rehabilitation was positively correlated with risk level (Group 1, 0.9% vs. 2.4%; Group 2, 3.0% vs. 4.2%; Group 3, 10.5% vs. 17.3%).Cardiac rehabilitation prescription was inversely correlated with patient risk. A positive association between cardiac rehabilitation and 1-year survival after acute myocardial infarction was present whatever the risk level, but the greatest mortality reduction was observed in high-risk patients.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results